Virginia G Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ 85238, USA.
Expert Opin Investig Drugs. 2010 Aug;19(8):1007-16. doi: 10.1517/13543784.2010.504708.
Since first reported just over 30 years ago, some progress has been made in our understanding of thymic cancer - an extremely rare cancer - and how to treat it. However, we are far from the ultimate goal of cure for most patients.
This review provides an overview of the thymic gland's development; features of thymic carcinoma, including its molecular characterization, current staging, and treatment guidelines; and progress made to date for treating advanced disease, concluding with future directions and prospects.
As scientists apply new molecular tools to learn more about cancer, we find that even among common cancers, there exist heterogeneous subtypes necessitating different treatment paradigms. Thus, a one-size-fits-all approach to cancer treatment is being displaced with precision medicine to target the 'Achilles heel' of thymic tumors.
When approaching thymic carcinoma, we must identify the key driving forces to target its context(s) of vulnerability to ensure the greatest impact of treatment for patients with this extremely rare cancer.
自 30 多年前首次报道以来,我们对胸腺癌(一种极其罕见的癌症)及其治疗方法的理解已经取得了一些进展。然而,对于大多数患者来说,我们远未达到治愈的最终目标。
本综述概述了胸腺的发育; 胸腺癌的特征,包括其分子特征、当前分期和治疗指南;以及迄今为止治疗晚期疾病所取得的进展,最后介绍了未来的方向和前景。
随着科学家应用新的分子工具来更多地了解癌症,我们发现,即使在常见的癌症中,也存在需要不同治疗模式的异质性亚型。因此,针对癌症的一刀切治疗方法正在被精准医学所取代,以针对胸腺瘤的“阿喀琉斯之踵”。
在处理胸腺癌时,我们必须确定关键的驱动因素,以针对其脆弱性的背景进行靶向,以确保为患有这种极其罕见癌症的患者提供最大的治疗效果。